Neuralstem Announces Proposed Public Offering ROCKVILLE,

New Post Public Reply Private Reply Replies (1) Message Board

Sep 14, 2012 at 6:43 AM

Neuralstem Announces Proposed Public Offering

ROCKVILLE, Md. , Sept. 13, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced today its intention, subject to market and other conditions, to commence a public offering of its common stock. Neuralstem intends to use the net proceeds from the offering for general corporate purposes, including research and development expenditures, working capital, capital expenditures, clinical trial expenditures and other general corporate purposes.

Aegis Capital Corp. is acting as the sole book-running manager for the offering.

The offering is being made pursuant to a shelf registration statement that Neuralstem filed with the Securities and Exchange Commission ("SEC") and is effective. A prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the prospectus supplement and the accompanying prospectus relating to these securities may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY , 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com . Electronic copies of the prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov .

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Neuralstem
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig 's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended June 30, 2012 .

SOURCE Neuralstem, Inc.

Deanne Eagle - Media Relations, +1-917-837-5866; Susan Roush - Investor Relations, +1-818-222-8330

Palisade Bio, Inc. (PALI) Stock Research Links

PALI Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BULL Faces Class Action After Regulatory Fines

Webull's Financial Quake Shakes Investors You don't expect to wake up to news of a stock in freefall, but here we are with Webull (NASDAQ:BULL) cratering after some rough compliance problems came to light. On November 5, 2026, Webull's stock tumbled nearly 11% thanks to FINRA slapping them with a $4.2 million fine for failing to keep their anti-money laundering (AML) and...

GTEC Faces Nasdaq Bid Price Compliance Challenge

Greenland Technologies in a Tight Spot Man, stocks can be as unpredictable as a cat on a hot tin roof, and Greenland Technologies Holding Corporation (Nasdaq: GTEC) just got a cold splash of reality from Nasdaq. On November 10, 2026, they were handed a Notification Letter that ain’t exactly a love note. Their shares slipped below the one-buck hurdle, and Nasdaq isn’t...

U-wifi Gains Charlie Vogt: Key Steps in 5G Expansion

Charlie Vogt Joins U-wifi: A Broadband Game Changer? There's a new player in town shaking things up, and he's no rookie. Charlie Vogt, five-time technology CEO and Managing Director at Bowen, is hopping onto U-wifi's board of directors. This isn't just about another corporate announcement; it's like adding a veteran quarterback to your expansion team. Vogt’s pedigree in...

Partner Joins Yardi ICN, Boosting Data Quality for Clients

Strategic Alliances in Real Estate Data When Partner Engineering and Science, Inc. says they're hooking up with the Yardi Independent Consultant Network (ICN), that's not just some boardroom handshake. It's a play that could shake up data services in the real estate game. Look, there's plenty of chatter about digitizing property management, but without killer data, those...

Choosing Screen-Free Outdoor Gifts: besrey's Top Picks

The Art of Choosing Outdoor Gifts for Kids Christmas time, my friends, isn't just about plastic gimmicks and gadgets vying for kids' attention. Nope, it's about making thoughtful decisions that blend discovery, movement, and a little peace of mind for parents. This time around, besrey's got the scoop on screen-free gifts that might just do the trick—helping kids explore...

SAHZU Hospital Earns GHA Distinction for Travel Care

A New Benchmark in International Patient Experience When a hospital sets the standard for treating foreign patients like family, it deserves recognition. That's exactly what's happened at The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU), which just snagged an impressive accolade from Global Healthcare Accreditation (GHA). For anyone keeping...

Cemig and Huawei's Bold Network Leap: Power Up

By Ryan Hughes Updated Nov 13, 2026 Category News Views 100

Taking the Leap in Brazil's Power Grid In Brazil, energy distribution's a whole different beast, and boy, is it complicated! Cemig found out the hard way that relying on public networks was a risky bet. Consistently bad. With a measly 50% coverage in Brazil's vast lands, you're looking at a communications nightmare, especially in the back of beyond where grid faults could...

Revolutionary Sports Ball Backpack: A Game Changer?

Backpacks Reinvented by a Clever Mom Ever been caught in the whirlwind of juggling kids, sports gear, and school supplies? Well, one stay-at-home mom from Poway, California found herself in just such a predicament. She turned this everyday chaos into a creative solution by designing a unique Sports Ball Backpack. The idea came to her while managing a toddler, a newborn,...

DEEPBLUE's Panelized Systems Target Low-Rise Markets

Changing the Game in Low-Rise Construction Been around the block a few times and seen all sorts of hype in this industry, but what DEEPBLUE SMARTHOUSE is pushing sounds more like evolution than revolution for low-rise builds. They're leaning into this panelized building system like a boxer on the ropes—that's their strategy to keep things steady and predictable. The...

DraftKings Shares Tumble, Investors Grapple with Losses

DraftKings' Bold Moves Hit Investor Pockets Hard It ain't every day you see a company gamble nearly $700 million and come out with egg on its face. Yet, that's what DraftKings (NASDAQ: DKNG) seems to have done, and now it's shareholders who might be left holding the bag. On November 6, 2026, when DraftKings admitted it was doubling down on its Predictions business...